Economics of Next Generation Sequencing - February 17, 2015

Genomics|Features|Economics

Economics of Genomic Medicine

Economics of Next Generation Sequencing - February 17, 2015

Next Generation DNA Sequencing: A review of the cost effectiveness and guidelines
Ottawa (ON):Canadian Agency for Drugs and Technologies in Health 2014 Feb 6.

The cost-effectiveness of clinical sequencing
Veenstra D et al. Institute of Medicine Discussion Paper, February 2015

The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.
Bennette Caroline S et al. Genet. Med. 2014 Nov 13.

How behavioral economics can help to avoid 'The last mile problem' in whole genome sequencing.
Blumenthal-Barby Jennifer S et al. Genome Med 2015 (1) 3

Genome sequencing: a systematic review of health economic evidence.
Frank Martin et al. Health Econ Rev 2013 (1) 29

Is the "$1000 Genome" really $1000? Understanding the full benefits and costs of genomic sequencing.
Phillips Kathryn A et al. Technol Health Care 2015 Feb 6.

Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.
Gallego Carlos J et al. Contemp Clin Trials 2014 Sep (1) 1-8

Economics of Genomic Medicine: Recent Insights - October 2, 2014

The business of genomic testing: a survey of early adopters. 
James M. Crawford et al. Genetics in Medicine, July 10, 2014 
   
CDC Commentary: Utility before business. 
Teutsch S et al. Genetics in Medicine, July 10, 2014.

The economics of genomic medicine: Institute of Medicine workshop summary 2013)

CDC paper: Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility.  
Scott D. Grosse. Genetics in Medicine (2014)

The economic value of personalized medicine tests: what we know and what we need to know. 
Kathryn A Phillips et al. Genetics in Medicine (2013)

Genomic sequencing: Assessing the health care system, policy, and big-data implications
Kathryn A. Phillips, et al. Health Affairs, July 2014 

Recent Publications

A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
Snowsill T1, et al. Health Technol Assess. 2014 Sep;18(58):1-406. doi: 10.3310/hta18580.

Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention 
Patel V, et al. Pharm Pract (Granada) 2014 Jul;12(3):438

Cost-effectiveness of IL28Beta genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 Infection 
Bock JA, et al. Public Health Genomics 2014 Sep

Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data 
van der Ploeg CP, et al. J Cyst Fibros 2014 Sep

The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis 
Beulen L, et al. Eur J Obstet Gynecol Reprod Biol 2014 Aug;182C:53-61

Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective. 
Miguel Ángel Seguí et al.  Expert Review of Pharmacoeconomics & Outcomes Research September 12, 2014